Epidemiology

Bladder Cancer Before 50: A Growing Global Burden

Bladder cancer is predominantly associated with older adults, but a global analysis suggests that the number of cases occurring before age 50 has increased substantially over the past three decades. Researchers examining early-onset bladder cancer found that new cases increased by more than 60% worldwide between 1990 and 2021. Although mortality rates have moved downward, the growing number of younger adults affected highlights a patient population that may receive comparatively little attention in bladder cancer research and clinical discussions.

Using Global Burden of Disease 2021 data, investigators evaluated bladder cancer among individuals aged 15 to 49 across 204 countries and territories. The analysis examined incidence, prevalence, mortality, and disability-adjusted life years from 1990 through 2021. During that period, the estimated annual number of new early-onset bladder cancer cases increased from approximately 19,147 to 31,054, a 62.2% increase. Prevalence increased by 73.1%, while the age-standardized incidence rate rose from 0.71 to 0.79 per 100,000.

Mortality followed a somewhat different trajectory. The absolute number of deaths increased by 15.3%, from approximately 5,487 in 1990 to 6,328 in 2021, but the age-standardized mortality rate declined by approximately 21%. Disability-adjusted life years showed a similar pattern, with the absolute burden increasing while the age-standardized rate decreased. Together, these findings suggest that a growing number of younger adults are being affected even as population-adjusted measures of fatal disease burden have improved.

Age and sex were also strongly associated with disease burden. Among individuals younger than 50, incidence, mortality, prevalence, and disability-adjusted life years were highest in the 45-to-49-year age group, followed by those aged 40 to 44. Men experienced substantially greater disease burden than women, with rates among adults older than 30 at least twice as high in men across the measures examined. Smoking remained the leading risk factor evaluated in the analysis, accounting for an estimated 18.55% of early-onset bladder cancer mortality and disability-adjusted life years, while high fasting plasma glucose accounted for a smaller but increasing proportion.

For urologists, the findings provide a broader perspective on bladder cancer occurring outside its typical older patient population. Early-onset disease remains uncommon, and the analysis relied on modeled Global Burden of Disease estimates rather than individual patient-level clinical data. Still, the increase in absolute case numbers reinforces the importance of recognizing that bladder cancer can occur in younger adults, particularly as they approach their 40s. Additional research using detailed clinical cohorts will be needed to determine what is driving these patterns and whether early-onset bladder cancer differs meaningfully in its presentation, biology, or clinical course.